Oruka Therapeutics, Inc.

NASDAQ:ORKA

Biotechnology

Healthcare
$95.74 +0.65%

+$0.46 today

Market cap
$6.49B
Beta
-0.30
P/E (TTM)
-33.9
EPS (TTM)
-$2.11
52W Low $10.77High $91.00

Volume 0.52M

Average 1.55M

ORKA Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Oruka Therapeutics, Inc.NASDAQ: ORKA

Weighted Avg Shares (Diluted) · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q3 FY2026 weighted avg shares (diluted) of 71.59M shares rose 62.5% year over year, behind the +68.6% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 13.9% from the prior quarter. Over 3 fiscal years it compounded at +46.8% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +62.5% toward the trailing-twelve-month pace of +68.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
71.59M+13.9% QoQ
Last fiscal yearDec 2025
45.61M+171.7% YoY
LTMSep 2026
61.01M+68.6% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+62.5%——
1 year+171.7%——
3-year CAGR+46.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
45.61M USD
Year-over-year change
+171.7%
4-year CAGR
+34.6%

Weighted Avg Shares (Diluted) vs competitors

How ORKA compares with its peers on the latest reported figures

  • ORKA's LTM Sep 2026 weighted avg shares (diluted) of 61.01M shares is the 6th highest of the 10 companies compared; the peer median is 65.6M shares.
  • Its year-over-year change of +68.6% is the 2nd highest of 10, against a peer median of +5.1%.
  • Over three fiscal years its annual growth of +46.8% compares with a peer median of +26.7%.
ORKA Competitors Peer median
Weighted Avg Shares (Diluted) for ORKA and competitors
Company Period LTM YoY 3-year CAGR
ACRSAclaris Therapeutics, Inc.LTM Mar 2026124.17M +37.8%+23.4%
ALMSAlumis Inc. Common StockLTM Jun 2026115.39M +93.6%+384.0%
ZURAZura Bio LimitedLTM Mar 202698.81M +34.9%+76.1%
XNCRXencor, Inc.LTM Jun 202674.94M +5.1%+7.6%
MLTXMoonLake ImmunotherapeuticsLTM Mar 202665.6M +4.1%+30.0%
ORKAOruka Therapeutics, Inc.LTM Sep 202661.01M +68.6%+46.8%
CNTBConnect Biopharma Holdings LimitedFY202555.66M +0.8%+0.4%
DNTHDianthus Therapeutics, Inc.LTM Jun 202644.91M +27.5%+116.1%
ATTOAttovia Therapeutics, Inc.FY202543.03M +0.0%—
ANABAnaptysBio, Inc.LTM Mar 202629.47M +0.4%+3.6%
ODTXOdyssey Therapeutics, Inc.—— ——
Peer median (excluding ORKA) 65.6M+5.1%+26.7%

Competitors are the stored peer set for ORKA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue91K114K111K27K83K
Gross Profit(91K)(114K)(111K)(27K)(83K)
Gross Margin—————
Research & Development13.83M4.46M1.01M75.06M100.64M
Selling, General & Admin5.41M5.26M6.17M13.04M21.33M
Operating Expenses19.24M9.73M7.19M88.1M121.97M
Depreciation & Amortization91K114K111K27K83K
EBITDA(19.23M)(9.81M)(5.23M)(82.23M)(105.35M)
EBITDA Margin—————
Operating Income(19.34M)(9.84M)(7.3M)(88.12M)(122.05M)
Operating Margin—————
Interest Income0675K1.96M5.86M16.63M
Interest Expense0001.47M0
Other Income / Expenses13K(85K)1.96M4.4M16.62M
Income Before Tax(19.32M)(9.93M)(5.34M)(83.72M)(105.43M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(19.32M)(9.93M)(5.34M)(83.72M)(105.43M)
Net Margin—————
EPS (Basic)(16.68)(8.27)(4.44)(4.99)(2.31)
EPS (Diluted)(16.68)(8.27)(4.44)(4.99)(2.31)
Weighted Avg Shares13.9M14.41M14.42M16.79M45.61M
Weighted Avg Shares (Diluted)13.9M14.41M14.42M16.79M45.61M

Oruka Therapeutics, Inc.

NASDAQ:ORKA

Intrinsic Alpha fair value

Locked

Current Price

$95.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.